Patient Derived Xenograft Models Market Scope And Analysis

Report Code : TIPRE00021693
Category : Life Sciences

No. of Pages : 150

Buy Now

Patient-Derived?Xenograft Model Market Scope and Analysis by 2030

Buy Now

Patient-Derived�Xenograft Model Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 378.46 Million
Market Size by 2030	US$ 975.31 Million
Global CAGR (2022 - 2030)	12.6%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Model Type Mice Models and Rats Models By Tumor Type Gastrointestinal Tumor Models Gynecological Tumor Models Respiratory Tumor Models Other Tumor Models By Application Preclinical Drug Development Biomarker Analysis Translational Research Biobanking By End User Pharmaceutical and Biotechnology Companies Contract Research Organizations Academic and Government Research Institutions
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Champions Oncology Inc Charles River Laboratories Inc Crown Bioscience Inc EPO Berlin Buch GmbH Hera BioLabs Horizon Discovery Group plc Oncodesign Pharmatest Services Ltd Xentech SAS

Industry Developments and Future Opportunities:

Initiatives taken by market players operating in the global patient-derived xenograft model market are listed below:

In July 2022, GemPharmatech entered a strategic licensing arrangement with Charles River Laboratories. The partnership involves the exclusive distribution rights for GemPharmatech's next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines within North America.
In November 2021, Inotiv Inc. completed the acquisition of Envigo RMS Holding Corp., a globally leading provider of research models and services.

Competitive Landscape and Key Companies:

The patient-derived xenograft model market forecast can help stakeholders plan their growth strategies. Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation are among the prominent players in the market. The market players focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.